These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1684309)

  • 1. The current unsatisfactory state of relapse prevention in schizophrenic psychoses--suggestions for improvement.
    Kissling W
    Clin Neuropharmacol; 1991; 14 Suppl 2():S33-44. PubMed ID: 1684309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of relapse in chronic schizophrenic patients.
    Hogarty GE
    J Clin Psychiatry; 1993 Mar; 54 Suppl():18-23. PubMed ID: 8097193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Our knowledge is patchwork. Survey on the adherence to international guidelines concerning acute and long-term therapy in recurrent depressions and diseases in the schizophrenic field].
    Ramseier F
    Praxis (Bern 1994); 1996 Jun; 85(24):792-7. PubMed ID: 8701169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?
    Gaebel W; Frick U; Köpcke W; Linden M; Müller P; Müller-Spahn F; Pietzcker A; Tegeler J
    Br J Psychiatry Suppl; 1993 Sep; (21):8-12. PubMed ID: 8105814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention of relapse in schizophrenia is discontinued too soon. Many colleagues make this mistake!].
    Seemann U; Kissling W
    MMW Fortschr Med; 2000 Feb; 142(5):34-8. PubMed ID: 10715937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance therapy and the natural course of schizophrenia.
    Davis JM
    J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):18-21. PubMed ID: 2865252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuation electroconvulsive therapy for relapse prevention in middle-aged and elderly patients with intractable catatonic schizophrenia.
    Suzuki K; Awata S; Takano T; Ebina Y; Iwasaki H; Matsuoka H
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):481-9. PubMed ID: 16048455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A study on relapse of schizophrenic patients--10-year-follow-up investigation after initial admission].
    Uchida S
    Seishin Shinkeigaku Zasshi; 1996; 98(5):299-319. PubMed ID: 8741284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of relapse prevention in schizophrenia.
    Müller N
    Pharmacopsychiatry; 2004 Nov; 37 Suppl 2():S141-7. PubMed ID: 15546066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of early warning signs in schizophrenic patients. Possible applications in prevention of recurrence].
    Wiedemann G; Hahlweg K; Hank G; Feinstein E; Müller U; Dose M
    Nervenarzt; 1994 Jul; 65(7):438-43. PubMed ID: 7800087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Modification of long-term schizophrenia by somato-therapeutic measures].
    Gross G; Huber G; Schüttler R
    Psychiatr Clin (Basel); 1980; 13(3-4):179-92. PubMed ID: 6113621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic medication: clinical guidelines for maintenance therapy.
    Johnson DA
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
    Gaebel W; Möller HJ; Buchkremer G; Ohmann C; Riesbeck M; Wölwer W; Von Wilmsdorff M; Bottlender R; Klingberg S
    Eur Arch Psychiatry Clin Neurosci; 2004 Apr; 254(2):129-40. PubMed ID: 15146342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term medication in schizophrenic psychoses].
    Gaebel W
    Fortschr Neurol Psychiatr; 2000 Apr; 68 Suppl 1():S26-31. PubMed ID: 10907610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
    Faraone SV; Brown WA; Laughren TP
    J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compliance, quality assurance and standards for relapse prevention in schizophrenia.
    Kissling W
    Acta Psychiatr Scand Suppl; 1994; 382():16-24. PubMed ID: 7916524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The risk of neuroleptic discontinuation in schizophrenia].
    Jarema M
    Psychiatr Pol; 1999; 33(1):69-81. PubMed ID: 10786216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing relapse in the long-term course of schizophrenia.
    Ayuso-Gutiérrez JL; del Río Vega JM
    Schizophr Res; 1997 Dec; 28(2-3):199-206. PubMed ID: 9468354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
    Hogarty GE
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):36-42. PubMed ID: 6143746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.